Document Type : Case Report


1 Kırıkkale University School of Medicine, Department of Anesthesiology and Reanimation, Kirikkale, Turkey

2 Kırıkkale University School of Medicine, Department of Neurosurgery, Kirikkale, Turkey


Bonsai is a synthetic cannabinoid (SC) substance which can cause lung toxicity with chronic use. However, there are few case reports in literature related to bonsai-induced intracerebral hemorrhage in literature. A 25-year-old man presented at the Emergency Room (ER) with dyspnea, hemoptysis and agitation subsequent to bonsai use. He became unconscious in ER and was then intubated and admitted to the intensive care unit (ICU). The cranial computed tomography (CT) scan was non-specific and a thoracic CT scan revealed consolidation and the appearance of “ground-glass” in the lung, and therefore, development of diffuse alveolar hemorrhage was considered. The patient recovered consciousness on the second day of hospitalization and was extubated. During follow-up, he lost consciousness once again and on the cranial CT images, hemorrhage areas located in the left frontal and right posterior parietal regions were observed. Nevertheless, no surgical intervention was considered. The patient recovered consciousness three weeks after the second intubation and was transferred to the psychiatry clinic. In patients with synthetic cannabinoid substance abuse, life-threatening intracranial complications in the early and/or late phase should be kept in mind in addition to respiratory and systemic complications in the acute phase.



Abuse and addiction of synthetic cannabinoid (SC) substances, known in different countries as “Spice”, “K2”, “Kronic”, “Bonsai”, “Jamaica”, has been increasing worldwide and has also become a serious social and health issue [1]. Psychomimetic symptoms have seen in the acute phase during the use of SC, while chronic use has been associated with many serious problems (e.g. psychiatric, neurological pulmonary, endocrinological and cardiovascular complications) and no specific treatment for SC intoxication has been established in literature other than supportive treatment [2-4]. The case is here presented of a patient with intracranial hemorrhage and alveolar hemorrhage due to the use of bonsai.


Case Report

A 25-year-old man was admitted to Emergency Room (ER) with complaints of dyspnea, hemoptysis, tachycardia and agitation which had developed immediately after use of “bonsai”. The medical history revealed that the patient had been treated in a hospital one year previously due to substance abuse and had been discharged after a rehabilitation program. It was also learned that he then attempted to re-use the substance after his discharge and had then been treated in an intensive care unit (ICU) of a hospital for 8 days and had been discharged 1 week previously. On examination of the patient, heart rate was 140 bpm and blood pressure was 156/89 mmHg. Blood biochemistry findings on admission to ER were as follows: hemoglobin 9.1 g/dL (reference range 10-18 g/dL), hematocrit 35.01% (reference range 30-55%), leukocyte 35100/uL (reference range 4400-11300/uL), neutrophil 28350/uL (reference range 100-9600/uL), lymphocyte 3870/uL (reference range 500-6000/uL), monocyte 2360/uL (reference range 100-1400/uL), eosinophil 410/uL (reference range0-100/uL), basophil 20/uL (reference range 3-300/uL), platelet 698000/uL (reference range 150000-500000/uL), alanine aminotransferase 18.57 U/L (reference range 5-41 U/L), aspartate aminotransferase 11 U/L (reference range 5-40 U/L), glucose 151 mg/dL (reference range 74-106 mg/dL), blood urea nitrogen 158.57 mg/dL (reference range 17-43 mg/dL), creatinine 5.68 mg/dL (reference range 0.66-1.44 mg/dL), calcium 7.91 mg/dL (reference range 8.8-10.6 mg/dL), sodium 138 mmol/L (reference range 136-146 mmol/L), potassium 4.83 mmol/L (reference range  3.5-5.1 mmol/L), C-reactive protein 46 mg/dL (reference range 0.15-5 mg/dL), PO2 80.2 mmHg, activated partial thromboplastin time (aPTT) 33.5 minutes (reference range 22-34 minutes), prothrombin time (PT)13.4 minutes (reference range 10-14 minutes), PT-international normalized ratio (INR) 1.21 (reference range 0.8-1.2), D-dimer 9.33 µg/mL (reference range 0-055 µg/mL) and fibrinogen 281 FIBmg/dL (reference range 180-350 FIBmg/dL).

The patient became unconsciousness after admission to the ER (Glasgow Coma Scale (GCS) score 4/15), so was intubated immediately. At that time, the brain computed tomography (CT) scan was seen to be normal (Figure 1). The patient was then admitted to ICU. The laboratory test results in ICU were as follows:  pH=7.21, PCO2=48 mmHg, PO2=44 mmHg, HCO3=17 mEq/L, BE=-8.6 mmol/L, and SpO2=71% in arterial blood gas examination, and blood glucose=149 gr/L, BUN=148 mg/dL, creatinine=5.6 mg/dL, and potassium=7.1 mmol/L. Emergency hemodialysis was applied after introducing an internal jugular vein catheter. The abdominal ultrasound was normal. Due to bleeding through the endotracheal tube, it was thought that alveolar hemorrhage had developed in the patient. Bilateral infiltration areas were seen on the lung X-ray and thoracic CT revealed bilateral pleural effusion and bilateral consolidation and areas of “ground-glass appearance”, more prominent on the right side, mostly involving peripheral-subpleural areas and including air bronchograms (Figure 2).  In addition, gram (-) bacteria was colonized in bronchoalveolar lavage sample culture. A triple antibiotherapy regimen was initiated, consisting of 400 mg teicoplanin once a day (Targocid, Gruppo Lepetit S.p.A., Italy), 1000 mg meropenem trihydrate twice a day (Meronem, AstraZeneca, UK) and 750 mg levofloxacin once a day (Tavanic, Sanofi Aventis, Turkey). When the patient regained consciousness (GCS score 15/15) two days later and the blood gas levels returned to normal intervals and hemodynamic stability was obtained, he was gradually extubated and oral feeding and mobilization was initiated. However, on the fourth day after admission, the patient became unconscious once again and arterial blood PaO2 was 40 mmHg and PCO2 was 85 mmHg and he was re-intubated. The brain CT scan revealed bilateral vasogenic edema in the cerebellar and cerebral hemispheres (Figure 3) and treatment of intravenous mannitol 20% (Neofleks, Eba Drug, Turkey) and phenytoin sodium (Epanutin, Pfizer, Turkey) was initiated. One week later, the brain CT and brain magnetic resonance (MR) scan (Figure 4) showed hematomas involving the ventricles in the existing left frontal and right posterior parietal hypoxic/ischemic areas. The neurosurgery consultant did not consider performing any surgical intervention to the patient. Three weeks after the second intubation, the patient regained consciousness and was gradually re-extubated. Self-mobilization was achieved two weeks after the extubation (Glasgow Outcome Scale score=5). It was observed that the previously detected infiltration areas on the chest radiography were markedly resolved and the intracranial hemorrhage (ICH), vasogenic edema, and hypoxic/ischemic areas previously detected on the brain CT had greatly improved (Figure 5). Based on these findings, the patient was discharged from the hospital with a recommendation for psychiatric consultation


Fig. 1. An axial brain computed tomography (CT) image obtained subsequent to the first episode of unconsciousness showing non-specific findings.


Fig. 2. Bilateralareas of infiltration are seen on the chest radiography taken because of the history of hemoptysis (2A). Thoracic computed tomography (CT) showing bilateral pleural effusion and consolidation areas including air bronchograms involving mostly peripheral-subpleural parts, more prominently in the right side and “ground-glass appearance” (2B, 2C). .


Fig. 3. Brain computed tomography (CT) image obtained subsequent to the second episode of unconsciousness showing bilateral vasogenic edema in cerebellar and cerebral hemispheres.


Fig. 4. Repeated cranial computed tomography (4A) obtained one week after the second episode of unconsciousness and diffusion (4B), ADC (4C), and FLAIR (4D) magnetic resonance images obtained subsequently showing development of hematomas involving the ventricle in the previously seen left frontal and right posterior parietal hypoxic/ischemic areas.


Fig. 5. A plain chest radiography obtained two weeks after extubation showing that the previously seen areas of infiltration were markedly diminished (5A) and cranial computed tomography showing that the areas of intracranial hemorrhage and vasogenic edema and hypoxic /ischemic areas were significantly improved (5B).



Synthetic cannabinoid agents can cause cerebral stroke, vasculitis, vasospasm, atrial fibrillation, tachycardia, tachyarrhythmia, xerostomia, diaphoresis, and mydriasis through direct sympathomimetic effects (Table 1) [5, 6]. However, the risk of intracranial hemorrhage due to SC substance abuse has not been completely identified in literature and it has been argued that these agents can cause acute ischemic stroke rather than ICH [7- 9]. Acute ICH related to SC substance abuse has been shown in only a few case reports in literature (Table 2) [10]. In the current case, although cranial MR images could not be taken in the early phase, cranial CT images on admission to the ER, which revealed no cerebral infarction or ICH, suggested that the unconsciousness of the patient had developed secondary to the toxicity of the bonsai rather than stroke. However, CT and MR images taken upon the re-development of unconsciousness in the late phase (approximately 4 days after the hospital admission of the patient) revealed bilateral vasogenic edema in the left frontal and right posterior parietal regions. These radiological images suggested that stroke had developed in the patient and this stroke was related to the SC agent abuse. One week later, brain CT and brain magnetic resonance (MR) scan showed hematomas involving the ventricles in the existing left frontal and right posterior parietal hypoxic/ischemic areas. These images suggested that intracerebral hemorrhage in that state might be related with hemorrhagic infarct secondary to ischemic stroke rather than coagulopathy secondary to the gram (-) bacterial infection which was already being treated with triple antibiotherapy regimen. All these findings suggested that this stroke developed secondary to SC substance abuse as discussed above.


Table 1. Most common clinical findings related to the synthetic cannabinoid exposures according to the Hoyte et al. [5].


N (%)


541 (40)


317 (23.4)


207 (15.3)


183 (13.5)


164 (12)


139 (10)


127 (9.4)


110 (8.1)


99 (7.3)

Chest pain

64 (4.7)


Table 2. Characteristics of patients with stroke related to cannabis and patients with stroke related to synthetic cannabinoids according to the Wolff et al. [10].

Variable (*)




Number of patients




Years of publication




Gender ratio




Mean age (range)


32.7 ± 12 (15–63)

29.3 ± 10.4 (15–48)

Chronic cannabinoids use


73 (86%)

6 (46%)

Tobacco use


59 (69%)

6 (46%)

Alcohol use


25 (29%)




77 (90%)

8 (61.5%)


IS b  







Hemorrhagic stroke


4 (5.8%)

5 (38.5%)






SAH d  















RCVS c  


26 (30%)

1 (7.7%)

Positive urinary screening


39 (46%)


Favorable outcome


34 (40%)

6 (54%)



5 (5.8%)


aICH: Intracranial hemorrhage; bIS: Ischemic stroke; cRCVS: Reversible cerebral vasoconstriction syndrome; dSAH: Subarachnoid hemorrhage; eSC: Synthetic cannabinoids; fTIA: Transient ischemic attack.


It has been demonstrated in current literature that diffuse alveolar hemorrhage (DAH) syndrome characterized by pulmonary hemorrhage, hemoptysis, respiratory distress and bilateral parenchymal consolidation may also develop secondary to the use of heroin, cocaine, and various cannabinoids [11]. In the present case, the development of dyspnea and hemoptysis following the SC substance abuse, the presence of supportive findings of hypoxia in the arterial blood gas analysis, the presence of bilateral pleural effusion and consolidation areas including air bronchograms involving mostly peripheral-subpleural parts, more prominently in the right side and the “ground-glass appearance” on thoracic CT images, and the presence of bleeding from the endotracheal tube supported the diagnosis of DAH secondary to SC agent toxicity.

In most cases, symptomatic and supportive treatment is recommended in the algorithms for the treatment of SC abuse-induced toxicity [4]. In the current case, symptomatic and supportive treatment was applied and the SC agent was expected to be eliminated from the patient’s body. When the patient became unconsciousness and hypoxic, he was intubated and followed up under mechanical ventilation. Subsequently, the patient underwent hemodialysis due to impaired renal functions. Moreover, bronchoalveolar mechanical cleansing and broad-spectrum antibiotherapy were initiated in addition to the respiratory support for DAH. Although no surgical intervention was performed for intracerebral hemorrhage, it was attempted to prevent possibly life-threatening complications which might develop subsequent to the hemorrhage with anti-edema and antiepileptic treatment.

In conclusion, the current case report showed that symptomatic and supportive treatment can be life-saving management in cases of intoxication following SC abuse. In addition, it should be kept in mind that respiratory and systemic complications can be seen commonly in the acute phase, whereas intracranial complications such as stroke and intracranial hemorrhage could onset in the early or late phases of intoxication. Therefore, it can be strongly recommended that patients are monitored closely for both systemic and intracranial complications during treatment in ICU.

  1. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131(1-2):106-11.
  2. Sevinc MM, Kinaci E, Bayrak S, Yardimci AH, Cakar E, Bektaş H. Extraordinary cause of acute gastric dilatation and hepatic portal venous gas: Chronic use of synthetic cannabinoid. World J Gastroenterol. 2015;21(37):10704-8.
  3. Barceló B, Pichini S, López-Corominas V, Gomila I, Yates C, Busardò FP et al. Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: A case series. Forensic Sci Int. 2017;273:e10-e4.
  4. Mills B, Yepes A, Nugent K. Synthetic Cannabinoids. Am J Med Sci. 2015;350(1):59-62.
  5. Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435-8.
  6. Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S. Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis. 2012;21(7):555-60.
  7. Kamat AS, Aliashkevich AF, Denton JR, Fitzjohn TP. Headache after substance abuse: a diagnostic dilemma. J Clin Neurosci. 2012;19(3):464-6.
  8. Ray WZ, Krisht KM, Schabel A, Schmidt RH. Subarachnoid hemorrhage from a thoracic radicular artery pseudoaneurysm after methamphetamine and synthetic cannabinoid abuse: case report. Global Spine J. 2013;3(2):119-24.
  9. Rose DZ, Guerrero WR, Mokin MV, Gooch CL, Bozeman AC, Pearson JM, et al. Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology. 2015;85(13):1177-9.
  10. Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy Behav. 2017;70(Pt B): 355-63.
  11. Riccardello GJ Jr, Maldjian PD. Pulmonary hemorrhage in acute heroin overdose: a report of two cases. Emerg Radiol. 2017;24(6):709-12.